Table 2. Correlation among the HLA-DQ gene dose, the number of potentially presented gluten peptides, and the relative risk for CD.
| HLA-DQ2 genotype | α/β-Chain combinations | Functional expression | Gluten epitopes presented | Haplotype risk of CD (9—11) |
|---|---|---|---|---|
| HLA-DR3 DQ2 | α0501, β0201 | + | All | High |
| HLA-DR3/7 DQ2 | α0501, β0201 | + | All | High |
| α0201, β0202 | + | Few | ||
| α0501, β0202 | + | All | ||
| α0201, β0201* | (+) | (Few) | ||
| HLA-DR3/X DQ2/X | α0501, β0201 | + | All | Low |
| αXXX, βXXX | — | — | ||
| α0501, βXXX | — | — | ||
| αXXX, β0201 | — | — | ||
| HLA-DR7 DQ2 | α0201, β0202 | + | Few | None |
*
Functional expression and T cell stimulation were not formally determined for this HLA-DQ2.2 transdimer, but this putative transdimer would have HLA-DQα1 and β1 domains identical with those of the HLA-DQ2.2 cis dimer and thus most likely possess identical peptide-binding properties